Kemanusiaan Vs Kapitalisme di Era Pandemi Corona Virus Disease-19 (COVID19): Ekslusifitas Paten Vs Lisensi Wajib
DOI:
https://doi.org/10.58258/jisip.v6i1.2714Keywords:
COVID-19 vaccine, developed countries, developing countriesAbstract
Corona Virus Disease-19 (COVID-19) began to spread to various parts of the world since December 2019, which was first discovered in Wuhan, China. Of course this has brought great disaster to 216 countries in the world, because no country is immune to this virus and the epidemic has spread to various continents and attacked many aspects of the world community. Distressing conditions like this require the state to play a stronger role by providing better service protection. In addition, conditions like this raise big questions about how countries in the world deal with this. In the midst of the COcVID-19 pandemic, many scientists are racing to quickly find an effective vaccine to fight this virus. An example of one that succeeded is the discovery of Sinovac or called CoronaVac, where this vaccine is the result of research from Sinovac Biotech Co. which is a biopharmaceutical company focused on research, development, manufacture and commercialization of vaccines, and the company is based in Beijing, China. Seeing the COVID-19 pandemic that is increasingly paying attention, especially in developing countries, many countries are pressing for the temporary waiver of COVID-19 vaccine patents during this crisis. The reason is none other than so that production can be accelerated so that it is expected to be able to handle the COVID-19 pandemic. Of course this raises a polemic between developed countries and developing countries where there are two different interests, one country protects its investors and the other one protects its people. From this we can see that COVID-19 leaves a lot of room for its own problems.Downloads
Published
2022-01-02
Issue
Section
Articles
License
Copyright Notice
Authors who publish with JISIP (Jurnal Ilmu Sosial dan Pendidikan) agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.Â
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.


